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457 Cystic ﬁbrosis − Pregnancy after IVF, CFTR Genotype:
p.[F508del]+[Q685PfsX4]
R. Gaillyova´1,2, I. Vala´sˇkova´1,2, A. Holcˇı´kova´3. 1University Hospital Brno,
Medical Genetics, Brno, Czech Republic; 2Masaryk University, Institute of
Biology, Brno, Czech Republic; 3University Hospital Brno, Clinic of Pediatric
Infectious Diseases, Brno, Czech Republic
Diagnosis Cystic Fibrosis was conﬁrmed in the patient in the age of 5 years, with
CFTR genotype: p.[F508del]+[Q685PfsX4].
The child is from ﬁrst pregnancy (IVF, 3rd cycle, twins, prematurity 34.week of
gestation, birth weight 2300 g, birth length 46 cm).
Genetic counselling with both parents was performed during pregnancy, due to
anamnese of Infertility were performed.cytogenetic analysis and analysis of CFTR
gene in both parents The karyotype was normal in both partners. The mother is a
carrier of mutation F508del in one CF allele. In the father ware 12 most frequent
mutations in CFTR gene in Czech population excluded (Inno Lipa). The invasive
prenatal diagnostics was not performed.
In the proband in age of 5 years was suspected the diagnosis of Cystic Fibrosis
(hypotrophy, repeated pneumonia, increased level chlorides in sweat).
DNA analysis of CFTR gene detected mutation F508del in one CFTR allele. After
analysis of 36 CF mutation we detectet CFTR genotype: p.[F508del]+[?].
The analysis continued by direkt sequencing of the CFTR gene and MLPA analysis
of CFTR gene. In the patient we detected mutation Q685PfsX4 on the second CF
allele.
We conﬁrm the CFTR Genotype: p.[F508del]+[ Q685PfsX4] in the patient and CF
genotype in the fater p.[ Q685PfsX4]+ [=].
In the family we recommend genetic counselling.
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458 Patient with delF508 and 5T/12xTG mutation
A. Hollsing1, M. Ka¨mpe1. 1Uppsala Univ Hospital, Uppsala CF Center, Uppsala,
Sweden
A 38-year-old woman, half-sister to one of our delF508/delF508 CF patients, was
blood sampled as part of a study (as healthy sibling). She has lived together with
her sister in the same family for 15 years, never thinking of any possibility of
herself having CF, never experiencing any ‘CF’ symptoms. She is of Icelandic
origin, nowadays living in Sweden, married and working as a teacher. She has been
smoking heavily about half her life and subsequently developed some phlegm,
cough and also shortage of breath, always thinking this was due to her smoking.
The blood sampling for genetic diagnosis, revealed her having a Cystic ﬁbrosis,
with not only delF508 from her mother, but also 5T/12xTG from her Icelandic
father. Further investigations reveal a normal sweat test, normal blood chemistry,
normal fecal elastase, normal vit A and E levels, negative sputum cultures, negative
serology (exotoxin for P. aeruginosa and alpha-toxin and teichoic acid for S. aureus),
no bronchiectasies but emphysema and bronchial wall thickening on a HRCT scan.
Newly introduced inhalation and airway clearance techniques have however reduced
the phlegm problems to hardly noticable, improved her breathing and coughing, now
raising her FEV1 from 40 to 67% of expected.
Conclusion: this mutation, 5T/12xTG, is known to be a mild mutation, but it is
unclear how common it is amongst CF patients. Without clear symptomatology,
negative sweat test, blood and sputum sampling, it is still important we can ﬁnd
these patients as they can beneﬁt tremendously from treatment.
459 Pseudomonas aeruginosa in cystic ﬁbrosis patients with CFTR
I1234V in a large kindred family
A. Abdul Wahab1. 1Hamad Medical Corporation, Pediatrics, Doha, Qatar
Aims and Objectives: To describe the characteristics of Pseudomonas aeruginosa
(P. aeruginosa) in cystic ﬁbrosis (CF) patients with CFTR I1234V in a large kindred
family in Qatar.
Methods: 46 patients of CF with CFTR I1234V from 25 families arising from a
single large Arab kindred tribe (5 CF sibling pairs, 3 families with 3 CF siblings,
2 with 4 and one family with 5) attending the CF clinic between May 2002 and
June 2008 were reviewed from clinical database and electronic laboratory database
at department of paediatrics at Hamad Medical Corporation (HMC). Thirty eight
CF patients, who were negative for P. aeruginosa at ﬁrst lower respiratory culture,
were enrolled in the study.
Results: The median (range) age was 13.8 (2.5–32.6). The prevalence of Pseu-
domonas aeruginosa (P. aeruginosa) in lower respiratory cultures was 60.9%.
Among 38 cystic ﬁbrosis (CF) patients with CFTR I1234V, 20 (52.6%) acquired
P. aeruginosa with no seasonal variation. Positive siblings with P. aeruginosa were
found in 70% indicating cross infection within the family. The median (range) age
at ﬁrst detection of P. aeruginosa was 12.5 (1−19) years. There was no signiﬁcant
difference between males and females in acquisition of P. aeruginosa.
P. aeruginosa of mucoid phenotype was detected in 11 (55%) of 20 with additional
organism with S. aureus being the most common organism in 9 (81.8%) of
11 CF patients.
Conclusion: A larger prospective study in a cohort of CF patients with CFTR
I1234V in the Arabian gulf region is required to determine the risk factors for
acquisition of P. aeruginosa with early aggressive antipseudomonal therapy.
460 Growth of Inquilinus limosus after visiting in Zimbabwe, Africa
A. Hollsing1, B. Herrmann2. 1Uppsala Univ Hospital, Uppsala CF Center,
Uppsala, Sweden; 2Uppsala Univ Hospital, Dept of Microbiology, Uppsala,
Sweden
This is a white male of 20 years, homozygeous for delF508, since a number of
years living and studying in Sweden. He is on medication and inhalation regimen
according to our routine. Due to exacerbations and coloured sputa, he has for many
years been treated intravenously against Pseudomonas aeruginosa (P.a.), despite
repeated negative cultures and serology (exotoxin A). Every single time he returns
from Zimbabwe, where his parents live, he has been in desperate need of treatment
and on suspicion of P.a. been given anti-pseudomonal treatment with in general
good recovery. Since a couple of years, again after returning from Zimbabwe, the
sputum cultures repeatedly reveal Inquilinus limosus with a multi-resistance pattern.
After iv treatment on exacerbations, also covering a possible P.a., he recovers and
returns to his studies. Despite prolonged culturing and parallell culturing at other
labs, no P.a., Burkholderia cepacia, Stenotrophomonas maltophilia, staphylococci
nor other bacteria have been found.
Conclusion: To our knowledge, no other CF patient in Sweden has been reported
to be colonized solely with his milieu bacteria, Inquilinus limosus. The relationship
to Zimbabwe is not likely incidental.
